This study aims to identify reliable prognosis markers to predict patient outcome at surgery in high-grade serous epithelial ovarian cancer by a real-time quantitative PCR (RT-q-PCR)-based test. Seventeen tissue samples from serous epithelial ovarian cancer patients were screened by DNA microarray to identify genes differentially expressed between tumors from patients who relapsed within 18 months and tumors from patients showing no relapse or relapsed after 24 months after initial diagnosis. RNA expression of a subset of genes was validated by RT-q-PCR in the initial set of 17 samples. From these results, a refined list was selected and tested in independent samples from 41 serous. Expression was associated with time to relapse and clinical variables. Microarray analysis identified a profile of 34 differentially expressed genes. RT-q-PCR validated the expression profile of a subset of seven genes in the initial set of patients. Differential gene expression was also validated in an independent set of patients. Low BTF4 or GCS expression was strongly associated with poor outcome in Kaplan-Meier analysis (P < 0.05, log-rank test) and Cox univariate as well as in multivariate analyses with a higher hazard ratio than clinical variables, such as residual disease, age, stage, and grade.